Inovio Pharmaceuticals Inc

-0.09 (-1.02%)
Twitter Share  Facebook Share StockTwits Share

Search For a Symbol

Market Cap (Intraday)1.80B
Current PEN/A
Forward PE N/A
2yr Forward PE 16.43
See more stats
Estimates Current Quarter
Revenue$1.06 Million
Adjusted EPS-$0.19
See more estimates
10-Day MA$9.06
50-Day MA$11.17
200-Day MA$13.44
See more pivots

Inovio Pharmaceuticals, Inc. Stock, NASDAQ:INO

660 West Germantown Pike, Suite 110, Plymouth Meeting, Pennsylvania 19462-1111
Phone: +1.267.440.4200
Number of Employees: 194


Inovio Pharmaceuticals, Inc. is a late-stage biotechnology company. It engages in the discovery, development, and commercialization of DNA-based immunotherapies and vaccines. The firm's drug candidates include SynCon immunotherapies which helps break the immune system?s tolerance of cancerous cells; and CELLECTRA delivery system which facilitates optimized cellular uptake of the SynCon immunotherapies. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.